← All trials
NCT06894745
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 2, 2025
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Mar 25, 2025
- Last posted
- Jul 22, 2025
- Enrollment
- 13
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- National Cancer Institute (NCI)Collaborator
- University of California, San FranciscoSponsor investigator
- ProLynx LLCCollaborator
- University of California, San FranciscoOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.